Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 10/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706704 | 0.96 | TP53 (0.59) | TP53POLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18707107 | 0.88 | NFE2L2 (0.53) | TP53POLBKEAP1NFE2L2 | |
| SCHEMBL1403058 | 0.86 | ALDH1A1 (0.60) | TP53POLBALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6311490 | 0.86 | KEAP1 (0.67) | TP53POLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18706440 | 0.84 | TP53 (0.58) | TP53POLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL26125537 | 0.84 | POLB (0.58) | TP53POLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18733335 | 0.84 | TP53 (0.58) | TP53POLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL31252550 | 0.84 | POLB (0.58) | TP53POLBHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL18706592 | 0.84 | HTT (0.59) | POLBHTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL13766911 | 0.83 | HTT (0.58) | TP53POLBHTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10351530-B2 | Arylcyclohexyl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-20180282283-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| EP-3371167-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060855-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282283-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | TP53 972/4885POLB 1908/4885HTT 2570/4885 |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | TP53 1359/4885POLB 1994/4885HTT 3171/4885 |
| US-10351530-B2 | Arylcyclohexyl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | TP53 972/4885POLB 1908/4885HTT 2570/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | TP53 1359/4885POLB 1994/4885HTT 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.